Maria D. Apkarian, BA

Vice President Clinical Operations
Vaxart Inc.
Phoenix, Arizona, United States

Disclosure information not submitted.

Presentation(s):

• 175 - An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Second Generation Oral Bivalent Vaccine Candidate

  Monday, October 20, 2025
  2:33 PM - 2:45 PM US ET